Home>>Signaling Pathways>> Proteases>> Endogenous Metabolite>>Taurochenodeoxycholic acid (12-Deoxycholyltaurine)

Taurochenodeoxycholic acid (12-Deoxycholyltaurine) Sale

(Synonyms: 牛磺鹅去氧胆酸; 12-Deoxycholyltaurine) 目录号 : GC33825

A quantitative analytical standard guaranteed to meet MaxSpec  identity, purity, stability, and concentration specifications

Taurochenodeoxycholic acid (12-Deoxycholyltaurine) Chemical Structure

Cas No.:516-35-8

规格 价格 库存 购买数量
10mM (in 1mL DMSO)
¥396.00
现货
50mg
¥360.00
现货

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

101

客户使用产品发表文献 1

Description

Taurochenodeoxycholic acid (TCDCA) is a taurine-conjugated form of the primary bile acid chenodeoxycholic acid .1 Serum levels of TCDCA increase approximately 5-fold within two hours and begin to decrease within four hours during an oral lipid tolerance test in humans.2 Serum levels of TCDCA are increased in patients with liver cirrhosis and may serve as a marker of disease progression.3

TCDCA MaxSpec  standard is a quantitative grade standard of TCDCA that has been prepared specifically for mass spectrometry and related applications where quantitative reproducibility is required. The solution has been prepared gravimetrically and is supplied in a deactivated glass ampule sealed under argon. The concentration was verified by comparison to an independently prepared calibration standard. The verified concentration is provided on the certificate of analysis. This TCDCA MaxSpec  standard is guaranteed to meet identity, purity, stability, and concentration specifications and is provided with a batch-specific certificate of analysis. Ongoing stability testing is performed to ensure the concentration remains accurate throughout the shelf life of the product. Note: The amount of solution added to the vial is in excess of the listed amount. Therefore, it is necessary to accurately measure volumes for preparation of calibration standards. Follow recommended storage and handling conditions to maintain product quality.

牛磺酸基合成的原胆酸对羟基基团的一种共轭物质,称为牛磺酸基合成的降解胆酸,它是主要的胆汁酸之一。1 在口服脂质耐受性试验中,人体血清中的TCDCA水平在两小时内增加了约5倍,并在四小时内开始下降。2 肝硬化患者的血清TCDCA水平增加,可能作为疾病进展的标志物。3

TCDCA MaxSpec标准是一种定量级别的TCDCA标准,专门为质谱和相关应用而制备,需要量化重现性。该溶液经过重量法制备,密封在惰性气体氩气下的失活玻璃安瓿中提供。通过与独立制备的校准标准进行比较,已验证浓度。验证的浓度提供在分析证书上。该TCDCA MaxSpec标准保证符合标识、纯度、稳定性和浓度规范,并提供具有批次特异性的分析证书。持续进行稳定性测试以确保在产品的货架寿命期间浓度保持准确。注意:加入到小瓶中的溶液量超过了所列数量。因此,需要准确测量体积以准备校准标准。遵循推荐的存储和处理条件以维护产品质量。

1.Hoffman, A.F.The continuing importance of bile acids in liver and intestinal diseaseArch. Intern. Med.159(22)2647-2658(1999) 2.Schmid, A., Neumann, H., Karrasch, T., et al.Bile acid metabolome after an oral lipid tolerance test by liquid chromatography-tandem mass spectrometry (LC-MS/MS)PLoS One11(2)e0148869(2016) 3.Wang, X., Xie, G., Zhao, A., et al.Serum bile acids are associated with pathological progression of hepatitis B-induced cirrhosisJ. Proteome Res.15(4)1126-1134(2016)

实验参考方法

Animal experiment:

Rats: Male Wistar rats are divided into six groups of ten each. Group 1 is normal rat (Sham), Group 2 received FCA only, Group 3 and Group 4 received FCA+Taurochenodeoxycholic acid (0.1 g/kg) and FCA+Taurochenodeoxycholic acid (0.2 g/kg), respectively, Groups 3 and 4 are treated beginning from day 0 of injection of FCA, Group 5 and Group 6 received FCA+Taurochenodeoxycholic acid (0.1 g/kg) and FCA+Taurochenodeoxycholic acid (0.2 g/kg), respectively, Group 5 and Group 6 are treated from 14 days after induction. All animals are treated with intragastrical administration and sacrificed after 28 days of induction[4].

References:

[1]. Wang X, et al. Taurochenodeoxycholic acid induces NR8383 cells apoptosis via PKC/JNK-dependent pathway. Eur J Pharmacol. 2016 Sep 5;786:109-15.
[2]. Zhou C, et al. The effects of taurochenodeoxycholic acid in preventing pulmonary fibrosis in mice. Pak J Pharm Sci. 2013 Jul;26(4):761-5.
[3]. Uchida A, et al. Taurochenodeoxycholic acid ameliorates and ursodeoxycholic acid exacerbates small intestinal inflammation. Am J Physiol. 1997 May;272(5 Pt 1):G1249-57.
[4]. Liu M, et al. Effects of taurochenodeoxycholic acid on adjuvant arthritis in rats. Int Immunopharmacol. 2011 Dec;11(12):2150-8.

化学性质

Cas No. 516-35-8 SDF
别名 牛磺鹅去氧胆酸; 12-Deoxycholyltaurine
Canonical SMILES C[C@@]1([C@@]2([H])[C@H](C)CCC(NCCS(=O)(O)=O)=O)[C@](CC2)([H])[C@@]([C@@H](C[C@]3([H])C[C@H](O)CC4)O)([H])[C@]([C@]34C)([H])CC1
分子式 C26H45NO6S 分子量 499.7
溶解度 DMSO : ≥ 25 mg/mL (50.03 mM) 储存条件 Store at RT
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 2.0012 mL 10.006 mL 20.012 mL
5 mM 0.4002 mL 2.0012 mL 4.0024 mL
10 mM 0.2001 mL 1.0006 mL 2.0012 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置

产品文档

Quality Control & SDS

View current batch: